Lizama BN, Reaver AJ, Pandey K, et al. Unbiased proteomic and transcriptomic analysis of Sigma-2 receptor modulation in an in vivo model of synucleinopathy. Poster presented Nov 2023 at: Society for Neuroscience (SfN) annual meeting; Washington DC.
Lizama B, Waybright L, Malagise E, et al. Unbiased Transcriptomic Analysis of the sigma-2 Modulator, CT1812 in Cell-based Models of Dry Age-related Macular Degeneration. Poster presented at: 2023 Association for Research in Vision & Ophthalmology
Lizama BN, Kahle J, Catalano SM, et al. Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases. Int. J. Mol. Sci. 2023, 24(7), 6251.
Izzo NJ, LaBarbera KM, Yuede CM, et al. Experimental Therapeutic CT1812 Demonstrates Target Engagement in a Phase 1b Clinical Trial to Measure Displacement of Aβ Oligomers Into CSF. Poster presented at: AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases; Barcelona, Spain.
Rishton GM, Look GC, Ni Z-J, et al. Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer’s Disease. ACS Med Chem Lett. 2021 Aug 9;12(9):1389-1395.
Cognition publishes evidence that treatment with CT1812 improves disease-related biology in patients with Alzheimer’s disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
Cognition publishes findings identifying sigma-2 (σ-2) receptor as integral in Parkinson’s disease pathology
Izzo NJ, Colom-Cadena M, Riad AA, et al. Proceedings from the Fourth International Symposium on σ-2 Receptors: Role in Health and Disease. 7(6) ENEURO .0317-20.2020 1–7
Limegrover, CS, LeVine, H, III, Izzo, NJ, et al. Alzheimer’s Protection Effect of A673T Mutation May Be Driven by Lower Aβ Oligomer Binding Affinity. J Neurochem. 2020; 00: 1–15
Colom-Cadena M, Spires-Jones T, Zetterberg H, et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease. Alz Res Therapy 12, 21 (2020)
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease Read More »
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
